bpc 157 human evidence safety BPC-157: Interesting Biology, Limited Clinical Proof FDA scientists flag concerns with

For neuroprotection protocols, standard dosing uses 0.25 to 0.5 mg daily via subcutaneous or oral administration

BPC-157 is not approved by Health Canada or the FDA for human use

One user with 15-year patellar tendonitis reported dramatic initial improvement in the first two weeks, but then the progress drastically slowed despite experimenting with different doses and injection sites

Investigators have explored this peptide pairing for its potential to influence body weight regulation, insulin sensitivity, and lipid profiles in animal and cellular models, making it a promising candidate for advanced metabolic research protocols